Market Overview

OPKO Health Announces the Start of Phase 3 Clinical Trials of Rolapitant for the Prevention of CINV

OPKO Health, Inc. (NYSE: OPK) today announced that the Phase 3 clinical program for rolapitant is currently enrolling patients. This global program consists of two randomized, double-blind and placebo controlled clinical trials evaluating the efficacy of a single 200mg oral dose of rolapitant in patients receiving highly emetogenic chemotherapy, or HEC, and one clinical trial evaluating the efficacy of a single 200mg oral dose of rolapitant in patients receiving moderately emetogenic chemotherapy, or MEC. Approximately 2,400 cancer patients will participate.

Posted-In: News FDA

 

Related Articles (OPK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters